End-to-End Preclinical CRO Sourcing Support

Early Discovery Support

This category covers outsourced research activities used to identify, refine, and prioritize compounds, biologics, or therapeutic hypotheses in the earliest stages of a program. It often includes exploratory, iterative, and decision-driving studies designed to move from concept to validated lead candidates.

• Target validation and target engagement strategy support
• Hit identification, assay-enabled screening, and screening cascade design
• Hit-to-lead studies and structure-activity relationship support
• Lead optimization planning across potency, selectivity, stability, and developability
• Candidate ranking based on integrated biology, chemistry, and PK-readiness inputs

Typical Service Elements

• Biochemical and cell-based screening assays
• Binding, inhibition, activation, and selectivity panels
• Custom assay development for novel targets or mechanisms
• Reference compound benchmarking and competitor profiling
• Early developability screens for antibodies, peptides, small molecules, or other modalities
• Data packages supporting go / no-go decisions before deeper pharmacology work

Cellular and Functional Biology

In vitro biology services are widely used to characterize potency, pathway activity, cellular response, mechanism of action, and early evidence of relevance in disease-context models. These studies are often central to candidate differentiation and can be configured for standard panels or project-specific biology questions.

• Cell viability, proliferation, apoptosis, migration, and invasion assays
• Reporter assays, receptor activation assays, and pathway modulation studies
• Immune cell assays, cytokine profiling, and co-culture models
• Organoid, spheroid, 3D culture, and advanced disease-relevant systems
• Mechanistic follow-up using western blot, PCR, ELISA, flow cytometry, or imaging readouts

MOA and Confirmation Work

• Mechanism-of-action studies to explain observed efficacy or pathway changes
• Biomarker response characterization under treated versus control conditions
• Species-to-species comparison studies for translational planning
• Primary cell and disease-relevant in vitro model support
• Custom endpoint selection aligned with downstream in vivo or regulatory strategy

Providers in this category may vary significantly in available cell lines, disease expertise, assay transfer capability, instrument platforms, data depth, and turnaround time.

Efficacy and Disease Model Studies

In vivo pharmacology services support the evaluation of compound activity, dose response, route feasibility, proof-of-concept, and biological relevance in animal models. This category is especially important when moving beyond in vitro promise into whole-system response and therapeutic differentiation.

• Proof-of-concept and efficacy studies in standard or custom disease models
• Oncology, inflammation, immunology, metabolic, CNS, pain, bone, and rare disease models
• Xenograft, syngeneic, orthotopic, genetically modified, or induced model systems
• Dose range exploration, schedule optimization, and route-of-administration planning
• Combination therapy and comparator-arm study designs

Study Execution Considerations

• Species, strain, sex, age, and housing condition alignment
• Tumor implantation, model induction, or surgical procedure capability
• Imaging, body weight, clinical score, survival, and tissue collection endpoints
• Necropsy coordination, pathology support, and sample chain-of-custody workflows
• Bioanalytical and biomarker add-ons integrated into the same study plan

ADME and Exposure Characterization

DMPK and ADME work helps teams understand how a candidate behaves in biological systems, how long it persists, how it distributes, and whether exposure supports the intended pharmacology. These studies are commonly used to derisk candidates and guide dosing, formulation, and species selection decisions.

• In vitro ADME screening such as microsomal stability, hepatocyte stability, plasma stability, and protein binding
• Permeability and transporter-related studies
• Metabolite profiling, reaction phenotyping, and biotransformation support
• Rodent and non-rodent pharmacokinetic studies
• Single-dose, repeat-dose, IV, PO, SC, IP, or other route-specific PK designs

Common Decision Points

• Does exposure align with in vitro potency or in vivo efficacy findings?
• Are there species differences relevant to safety or translational planning?
• Is the compound suitable for the intended formulation and dosing schedule?
• Do metabolism findings raise DDI or instability concerns?
• What additional work is needed before IND-enabling or broader safety assessment?

The exact study package may include both screening and confirmatory work, and often benefits from close coordination with bioanalysis, formulation, and pharmacology teams.

Quantitative Analytical Support

Bioanalysis services support the quantification and characterization of drugs, metabolites, biomarkers, antibodies, conjugates, or other analytes in biological matrices. These studies are essential for PK, TK, exposure-response, immunogenicity, and sample-driven project decisions.

• LC-MS/MS method development, qualification, transfer, and routine sample analysis
• Ligand binding assays including ELISA, MSD, ECL, and other immunoassay formats
• Biological matrix testing in plasma, serum, whole blood, tissue homogenate, urine, CSF, and related matrices
• Anti-drug antibody and immunogenicity support
• Biomarker and cell-based analytical assays when linked to PK or PD questions

Workflow Fit

• Supports DMPK, in vivo pharmacology, toxicology, and translational studies
• Can be stand-alone or embedded within larger non-clinical packages
• Often requires method selection based on sensitivity, matrix effect, throughput, and regulatory expectation
• May be performed under research-use, non-GLP, or GLP-aligned conditions depending on project stage

Matching the right analytical platform to the modality and matrix is often one of the most important scoping decisions in outsourced non-clinical work.

Non-Clinical Safety Support

Toxicology and safety-related services help sponsors identify liabilities, characterize risk, and prepare for later-stage development decisions. Scope can range from exploratory screens through more formal non-clinical safety packages depending on intended use and development stage.

• General toxicology studies and dose-finding support
• Safety pharmacology-related workstreams
• Genetic toxicology and selected specialty safety services
• Tolerability and target-organ risk characterization
• Pathology, histology, necropsy coordination, and safety-related sample analysis

Study Planning Factors

• Species justification and route alignment
• Study duration and dose schedule considerations
• Exploratory versus formal documentation expectations
• Integration with TK, bioanalysis, pathology, and biomarker endpoints
• Internal sponsor timelines for development milestones or partnering events

Bridging Biology and Development Strategy

Translational support services are used to connect discovery findings with practical development decisions through biomarker selection, tissue analysis, mechanism-linked endpoints, and comparative biological evidence. This category is useful when programs need more than efficacy alone and require context for why a candidate is working, where it is acting, and how to differentiate it.

• Biomarker identification and validation support
• PK/PD and exposure-response framework development
• Tissue-based assays, IHC, multiplex analysis, and molecular endpoint support
• Translational species bridging and exploratory relevance studies
• Companion sample strategies for preclinical research settings

Where This Category Adds Value

• Programs preparing for partner discussions or financing milestones
• Assets requiring deeper biological narrative beyond simple activity readouts
• Mechanism-heavy projects where endpoint choice matters
• Studies that need coordinated tissue, imaging, molecular, and analytical outputs

Biomarker and translational work is often cross-functional and may sit across in vitro biology, in vivo pharmacology, pathology, and bioanalysis. A structured quote request helps reduce misalignment during provider selection.

Preparation and Characterization Support

Chemistry and analytical support services can help teams prepare materials for discovery, pharmacology, ADME, safety, and broader development activities. Depending on the provider, this may include medicinal chemistry support, reference standard preparation, impurity profiling, formulation screening, and selected early CMC-related work.

• Custom synthesis and medicinal chemistry support
• Compound purification, salt screening, and reference material support
• Analytical method development for identity, purity, and stability-related purposes
• Formulation feasibility and solubility-related study support
• Batch characterization and technical data package preparation

Why It Matters

• Provides better material consistency before outsourced biology or PK work
• Reduces downstream delays caused by formulation or analytical uncertainty
• Supports handoff between discovery-stage work and more formal development planning
• May be critical for difficult modalities or unstable compounds

Not every project needs broad chemistry support, but for programs with scalability, stability, purity, or formulation concerns, this category can materially improve outsourcing success.